Eye injection of special cells may reduce corneal swelling
NCT ID NCT05636579
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of injecting special human cells (EO2002) into the eye to treat corneal swelling. Twelve adults with corneal edema from Fuchs' dystrophy or after cataract surgery will receive multiple injections, with or without Ripasudil eye drops. The main goal is to see if the treatment is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EO2002 (magnetic human corneal endothelial cells) with or without Ripasudil eye drops
- What this could lead to
- If successful, this could point toward a new treatment for corneal swelling that might reduce the need for corneal transplants.
- What could go wrong
- This is a very early Phase 1 trial with only 12 people, so safety and effectiveness are not yet proven. The treatment involves injections into the eye, which carries risks like infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All ocular criteria apply to the study eye unless otherwise noted. 1. Age ≥ 18 years. 2. Subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus). 3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs' corneal dystrophy or pseudophakic bullous keratopathy. Key Exclusion Criteria: All ocular criteria apply to the study eye unless otherwise noted. 1. Other corneal disease 2. Anterior chamber intraocular lens 3. Sutured or scleral-fixated intraocular lens. 4. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA. 5. History of refractive surgery. 6. History of Vitrectomy 7. Descemet membrane detachment. 8. History of uveitis or other ocular inflammatory disease. 9. History of incisional glaucoma surgery (e.g.,trabeculectomy, glaucoma drainage implant). 10. IOP \>21 or \<7 mm Hg 11. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty. 11\. History of ocular neoplasm. 12. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200). 13\. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study. 14\. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration. 15\. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bullous keratopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Asociacion para Evitar la Ceguera en Mexico
RECRUITINGMexico City, Mexico City, 04030, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes drug shield aging blood vessels?
- A natural supplement combo could give hearts a boost
- Ancient herbal mix may shield blood vessels in diabetes
- Could a vitamin B3 pill undo early heart damage from childhood adversity?
- Could a pill shield the brain and kidneys during heart surgery?
- One shot to see clearly: cell therapy takes on corneal edema